The University of Michigan
Welcome,         Profile    Billing    Logout  
 59 Trials 
36 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hutchinson, Raymond J
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Recruiting
1
36
Canada, US, RoW
Marqibo
Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc
ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
08/21
12/22
Miller, Bruce L
NCT03511586: Total Shoulder Arthroplasty Multi-Center Registry

Recruiting
N/A
2500
Europe, US
Arthrex, Inc.
Shoulder Arthroplasty
07/25
11/27
Hyzy, Robert C
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
Kitko, Carrie
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Checkmark Pivotal data from ROCKstar trial in cGVHD
Jul 2021 - Jul 2021: Pivotal data from ROCKstar trial in cGVHD
Checkmark Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Jun 2021 - Jun 2021: Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Checkmark Follow-up data from ROCKstar trial for cGVHD at ASH
More
Terminated
2
159
US
Belumosudil (KD025), REZUROCK
Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
12/23
12/23
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
Khanna, Dinesh
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Smith, Yolanda R
NCT05144386: Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Completed
1
6
US
EBT-101
Excision BioTherapeutics
HIV-1-infection
11/24
11/24
McLaughlin, Vallerie
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
PaRTAkE-PH, NCT04254289: Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension

Withdrawn
N/A
54
US
Usual Care, Home-based exercise program
University of Michigan, Actelion
Pulmonary Arterial Hypertension
06/25
12/25
Pipe, Steve
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Recruiting
N/A
200
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
11/24
11/24
Napolitano, Lena M
NCT05057221: Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

Terminated
1/2
6
US
Uproleselan
Lena Napolitano, MD, GlycoMimetics Incorporated
COVID-19 Pneumonia
03/22
03/22
MIRO-01-001, NCT06285253: MiroliverELAP® for the Treatment of Acute Liver Failure: a Phase 1 Trial

Recruiting
1
15
US
miroliverELAP treatment
Miromatrix Medical Inc.
Acute Liver Failure, Acute Liver Injury, Drug Induced
01/25
02/25
Lugt, Mark Vander
RESKUE, NCT04693598: Gene Transfer Clinical Trial for Krabbe Disease

Active, not recruiting
1/2
6
US
FBX-101, AAVrh.10-hGALC
Forge Biologics, Inc
Krabbe Disease
07/24
07/24
REKLAIM, NCT05739643: Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

Active, not recruiting
1/2
9
US
FBX-101, AAVrh.10-hGALC
Forge Biologics, Inc
Krabbe Disease
11/26
11/26
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT06308718: Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Active, not recruiting
N/A
25
US
FBX-101
Forge Biologics, Inc
Krabbe Disease
11/26
11/26
Aslam, Muhammad F
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
Chen, Emily
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
NCT04698343: Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction

Completed
N/A
21
US
Noninvasive Peripheral Nerve Stimulation (NPNS)
Noctrix Health, Inc., National Institute of Neurological Disorders and Stroke (NINDS)
Restless Legs Syndrome
02/23
03/23
Varner, Connie
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
Wong, Jane
NCT05057221: Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

Terminated
1/2
6
US
Uproleselan
Lena Napolitano, MD, GlycoMimetics Incorporated
COVID-19 Pneumonia
03/22
03/22
Yessayan, Lenar
SARCA, NCT05339139: SAfety of Regional Citrate Anticoagulation ( Study)

Recruiting
3
50
US
Dialysis
Fresenius Medical Care North America
Acute Kidney Injury, ESRD
11/24
03/25
PURIFY-RCT, NCT05011656: Blood Purification for the Treatment of Pathogen Associated Shock

Recruiting
N/A
15
US
Seraph-100 + State of the Art Care, State of the Art Care
ExThera Medical Corporation, Uniformed Services University of the Health Sciences
Septic Shock
09/25
09/25
NEUTRALIZE-AKI, NCT05758077: Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury

Recruiting
N/A
200
US
Selective Cytopheretic Device, SCD, Standard of Care
SeaStar Medical, ICON plc
Acute Kidney Injury
12/25
09/26
Kratz, Anna
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
Asefa, Haila
NCT04899115: VE303 for Treatment of Hepatic Encephalopathy (HE)

Completed
2
19
US
Placebo, VE303, oral vancomycin
Patricia Bloom, Vedanta Biosciences, Inc., American College of Gastroenterology, American Association for the Study of Liver Diseases
Cirrhosis, Hepatic Encephalopathy
04/23
08/23
Walkovich, Kelly
NCT04154488: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
1/2
32
US
Mavorixafor, X4P-001
X4 Pharmaceuticals
Neutropenia
08/24
08/24
Cascino, Thomas
PaRTAkE-PH, NCT04254289: Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension

Withdrawn
N/A
54
US
Usual Care, Home-based exercise program
University of Michigan, Actelion
Pulmonary Arterial Hypertension
06/25
12/25
Mills, Ryan
NCT05796765: Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

Terminated
2
43
US
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
MiMedx Group, Inc., Rho, Inc., United BioSource, LLC, NBCD A/S
Knee Osteoarthritis
12/23
12/23
NCT03511586: Total Shoulder Arthroplasty Multi-Center Registry

Recruiting
N/A
2500
Europe, US
Arthrex, Inc.
Shoulder Arthroplasty
07/25
11/27
Klida, Catherine
No trials found
Rowell, Brigid
No trials found
Pongmala, Fay
No trials found
Fung, Chris
No trials found
Mahmood, Carmen Colmenero
No trials found
Pongmala, Chatkaew
No trials found
Contreas, Rocio
No trials found
Crandall, Amanda
No trials found

Download Options